These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 15738295)

  • 1. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
    Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
    Halank M; Kolditz M; Miehlke S; Schiemanck S; Schmeisser A; Hoeffken G
    Wien Med Wochenschr; 2005 Aug; 155(15-16):376-80. PubMed ID: 16160926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
    Kuntzen C; Gülberg V; Gerbes AL
    Gastroenterology; 2005 Jan; 128(1):164-8. PubMed ID: 15633133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
    Barth F; Gerber PJ; Reichen J; Dufour JF; Nicod LP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1117-9. PubMed ID: 16957519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
    Grander W; Eller P; Fuschelberger R; Tilg H
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():67-70. PubMed ID: 16919014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
    Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
    Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of portopulmonary hypertension with bosentan: case report.
    Stähler G; von Hunnius P
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():62-6. PubMed ID: 16919013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bosentan treatment for portopulmonary hypertension associated with syncope.
    Sato A; Maie K; Ohno Y; Yoshida T; Ito E; Tanabe Y; Aizawa Y
    Int Heart J; 2011; 52(4):243-5. PubMed ID: 21828952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-receptor antagonist treatment of portopulmonary hypertension.
    Hinterhuber L; Graziadei IW; Kähler CM; Jaschke W; Vogel W
    Clin Gastroenterol Hepatol; 2004 Nov; 2(11):1039-42. PubMed ID: 15551258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
    Sağ S; Yeşilbursa D; Güllülü S
    Turk J Gastroenterol; 2014 Aug; 25(4):429-32. PubMed ID: 25254528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis.
    Molnar C; Alber H; Colleselli D; Vogel W; Kähler CM
    Wien Klin Wochenschr; 2004 Sep; 116(17-18):627-30. PubMed ID: 15515882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
    Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
    Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.
    Savale L; Magnier R; Le Pavec J; Jaïs X; Montani D; O'Callaghan DS; Humbert M; Dingemanse J; Simonneau G; Sitbon O
    Eur Respir J; 2013 Jan; 41(1):96-103. PubMed ID: 22653773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.